SEARCH FOR BITARGET HDACi AND VEGFR-2 PREPARATIONS BASED ON A COMBINATION OF QUINAZOLIN-4(3H)-ONE DERIVATIVES VIA A LINKER WITH HYDROXAMIC ACID by Bondarenko, E. D. et al.
MOSM2019  Yekaterinburg, Russia  November 13-16  
 
OR-15 
 
SEARCH FOR BITARGET HDACi AND VEGFR-2 PREPARATIONS BASED  
ON A COMBINATION OF QUINAZOLIN-4(3H)-ONE DERIVATIVES VIA A LINKER  
WITH HYDROXAMIC ACID 
 
E.D. Bondarenko,1,2 A.R. Mavlianberdiev,1,2 A.V. Kolotaev,2 V.N. Osipov,2,3 A.N. Balaev,4  D.S. 
Khachatryan2 
 
1D. Mendeleev University of Chemical Technology of Russia, 
125047, Russia, Moscow, 9 Miusskaya Sq. 
2NRC “Kurchatov Institute”– IREA, 107076, Russia, Moscow, 3 Bogorodsky Val. 
3NMRC of oncology N.N. Blokhin, 115478, Russia, Moscow, 23 Kashirskoye Sh. 
 4JSC “Farm-Synthesis”, 121357, Russia, Moscow, Vereiskaya St., 29, b. 134. 
E-mail: djedaj12@mail.ru 
 
Abstract. Chemistry of hydroxamic acids is an intensively developing field of organic chemistry. Histone 
deacetylase enzymes (HDAC) exist that catalyze the removal of the histone ε-N-acetyl-lysine acetyl group.1 
Hydroxamic acids are able to inhibit these enzymes.  
Quinazolinones are also of great interest due to their pharmacophore properties. In particular, 
quinazolinones are tyrosine kinase inhibitors (VEGFR-2).2,3 
A promising direction today is the synthesis of drugs that combine in their composition the properties of 
the two described groups.  
 
Picture 1. Synthesis of bifunctional compounds based on quinazolinones and hydroxamic acids. R1 = H, CH3, OMe, 
Br; R2 = H, F; n = 4-6.  
In work it was discusses a strategy for creating bifunctional inhibitors, where hydroxamic acids are linked 
to qinazoline fragment. Various compounds of this type have been prepared that are potentially antitumor agents 
with dual targeting for HDAC and VEGFR-2.  
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